<DOC>
	<DOCNO>NCT01988506</DOCNO>
	<brief_summary>TRANSREG ass safety biological efficacy low-dose IL2 Treg inducer set 12 autoimmune auto-inflammatory disease , aim select diseases therapeutic development perform . Extensive biological- immune-monitoring pre- post-IL2 contribute ( ) define common distinct process responsible breakdown immunological tolerance pathology ( ii ) discover potential biomarkers IL2 response .</brief_summary>
	<brief_title>Induction Regulatory Cells Low Dose il2 Autoimmune Inflammatory Diseases</brief_title>
	<detailed_description>Protocol : TRANSREG multicentric , uncontrolled , open-label study , compare biological clinical response administration low dos IL2 across 12 selected pathology : rheumatoid arthritis , ankylose spondylitis , systemic lupus erythematosus , psoriasis , Behcet 's disease , Wegener 's granulomatosis , Takayasu 's disease , Crohn 's disease , ulcerative colitis , autoimmune hepatitis , sclerosing cholangitis Gougerot-sjögren . Methods : Each patient receive 1MUI /day IL2 Day-1 Day-5 ( induction period ) , every 2 week ( except systemic lupus erythematosus 's patient receive every week ) Day-15 Day-180 ( maintenance period ) . Patients thereafter follow 12 month ( Day-181-Day-540 ) . For pathology , 6 patient include Pitié-Salpêtrière , Cochin , Saint Antoine Paul Brousse hospital Paris . An interim analysis perform pathology group first six patient receive least 3 month treatment . In pathology group Treg response document , six additional patient include . In total , minimum 72 patient 132 patient enrol study . Primary efficacy endpoint Treg response Day-8 . Secondary endpoint : - Treg response maintenance period , - change marker inflammation - clinical response , evaluate mean global generic scale [ Clinical Global Impression severity scale ( CGI-sev ) Clinical Global Impression efficacy index ( CGI-eff ) ] well specific clinical biological evaluation disease , - frequency relapse , - assessment quality life ( scale EuroQL-5 ) .Expected Results : TRANSREG define patient respond IL2 , whether per pathology accord pre-treatment phenomics , allow guide clinical development low dose IL2 autoimmune auto-inflammatory disease .</detailed_description>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Behcet Syndrome</mesh_term>
	<mesh_term>Cholangitis , Sclerosing</mesh_term>
	<mesh_term>Hepatitis , Autoimmune</mesh_term>
	<mesh_term>Takayasu Arteritis</mesh_term>
	<mesh_term>Aortic Arch Syndromes</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>age &gt; 18 year male female document diagnosis one AIID among 12 disease select ( follow consensual specific criterion ) stable moderately active disease standard treatment ( ≥ 2 month ) time inclusion , normal thyroid function ( without treatment ) effective contraception two week inclusion negative beta HCG test woman childbearing potential , affiliated social security system write informed consent form . know intolerance IL2 ( see SPC ) , administration nonauthorized treatment and/or IV bolus corticosteroid last 2 month , vaccination live attenuate virus month precede inclusion plan study severe progressive autoimmune/inflammatory pathology , low white blood cell count &lt; 2000/mm3 , lymphocytes &lt; 600/mm3 , platelet &lt; 80 000/mm3 , heart failure ( ≥ grade III NYHA ) , renal insufficiency ( Cockcroft &lt; 60ml/mn except patient lupus Wegener 's granulomatosis ) hepatic insufficiency ( transaminases &gt; 5N except patient autoimmune hepatitis ) , lung failure , significant abnormality chest Xray link disease investigation cancer history cancer cure less five year ( except situ carcinoma cervix basocellular carcinoma ) poor venous access allow repeat blood test , restrictive diet parenteral nutrition , surgery last 2 month surgery plan study , participation biomedical research last 3 month plan study . pregnant lactate woman , concomitant psychiatric disease chronic illness drugabuse could interfere ability comply protocol give inform consent , positive HIV serology , active hepatitis B EBV infection , patient measure legal protection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>IL2 ,</keyword>
	<keyword>Interleukin 2 ,</keyword>
	<keyword>IL-2 ,</keyword>
	<keyword>Proleukin® , RhIL-2</keyword>
	<keyword>Auto-immune disease</keyword>
	<keyword>Inflammatory disease</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Regulatory T cell ,</keyword>
	<keyword>Treg</keyword>
	<keyword>Immunoregulation</keyword>
	<keyword>Immune tolerance</keyword>
</DOC>